Bliss GVS Pharma Ltd

₹ 278 -4.06%

15 May - close price

About

Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups.

Key Points

Product Portfolio:
The company manufactures, markets, and exports over 150 branded formulations across 60+ therapeutic segments, including anti-malarial, anti-fungal, anti-bacterial, antibiotic, anti-inflammatory, contraceptive, and anti-diabetic. It sells these formulations as suppositories, pessaries, capsules, tablets, and syrups. Its portfolio includes over 150 brands such as P-Alaxin, Lonart, Funbact, and Lofnac. ^[1] ^[2]

Website BSE NSE

Market Cap ₹ 2,937 Cr.
Current Price ₹ 278
High / Low ₹ 293 / 117
Stock P/E 29.9
Book Value ₹ 109
Dividend Yield 0.18 %
ROCE 12.8 %
ROE 8.88 %
Face Value ₹ 1.00

Add ratio to table

Edit ratios

Pros

Company has reduced debt.
Company is almost debt free.

Cons

Stock is trading at 2.54 times its book value
The company has delivered a poor sales growth of 9.41% over past five years.
Company has a low return on equity of 7.87% over last 3 years.
Dividend payout has been low at 11.4% of profits over last 3 years
Company has high debtors of 229 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	143	109	171	161	164	149	183	180	156	163	190	165	212
	133	98	129	133	139	122	157	154	142	131	160	138	167
Operating Profit	11	11	42	29	25	27	25	26	14	33	30	27	44
OPM %	8%	10%	25%	18%	15%	18%	14%	14%	9%	20%	16%	16%	21%
	6	7	11	8	-33	7	8	12	9	11	14	8	10
Interest	5	1	1	2	2	1	3	1	1	5	3	1	2
Depreciation	4	5	6	6	6	6	6	7	7	8	8	8	8
Profit before tax	8	11	46	29	-15	26	24	30	14	31	33	25	44
Tax %	28%	31%	26%	27%	-25%	26%	29%	29%	20%	31%	26%	26%	27%
	6	8	34	21	-11	19	17	21	11	21	25	19	32
EPS in Rs	0.59	0.72	3.25	1.98	-1.09	1.85	1.62	2.00	1.09	2.00	2.35	1.76	3.06
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	313	326	348	298	427	442	466	636	598	605	667	730
	227	230	247	209	331	342	374	527	508	498	575	596
Operating Profit	86	97	101	88	95	100	91	109	90	107	92	134
OPM %	28%	30%	29%	30%	22%	23%	20%	17%	15%	18%	14%	18%
	21	23	9	11	33	37	18	35	51	-8	36	42
Interest	11	14	9	7	3	7	4	4	10	6	7	11
Depreciation	5	6	6	6	6	9	14	14	15	24	27	31
Profit before tax	91	100	95	87	120	122	91	126	116	70	94	133
Tax %	34%	35%	38%	34%	38%	24%	26%	27%	26%	28%	27%	27%
	60	66	59	57	74	92	68	93	85	51	69	97
EPS in Rs	5.82	6.36	5.73	5.53	7.22	8.95	6.54	8.94	8.21	4.84	6.55	9.16
Dividend Payout %	12%	8%	10%	18%	14%	6%	8%	6%	6%	10%	8%	16%

Compounded Sales Growth
10 Years:	8%
5 Years:	9%
3 Years:	7%
TTM:	9%

Compounded Profit Growth
10 Years:	4%
5 Years:	8%
3 Years:	5%
TTM:	42%

Stock Price CAGR
10 Years:	10%
5 Years:	21%
3 Years:	55%
1 Year:	131%

Return on Equity
10 Years:	10%
5 Years:	9%
3 Years:	8%
Last Year:	9%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	10	10	10	10	10	10	10	10	10	10	11	11
Reserves	358	422	481	531	593	673	745	841	927	978	1,048	1,145
	90	81	75	94	72	93	92	90	81	78	68	13
	97	71	99	59	61	79	98	139	122	84	93	176
Total Liabilities	555	585	666	694	736	855	946	1,080	1,140	1,150	1,220	1,344
	82	79	76	73	79	180	175	225	326	331	369	420
CWIP	0	2	2	0	43	0	2	22	3	8	21	4
Investments	19	21	21	18	18	18	18	18	18	19	19	19
	454	483	567	602	596	657	750	815	793	793	812	901
Total Assets	555	585	666	694	736	855	946	1,080	1,140	1,150	1,220	1,344

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	15	60	38	23	48	63	67	114	44	82	97	123
	-19	-15	-29	16	-68	-60	-62	-92	-13	-66	-78	-51
	-31	-35	-15	-22	9	-6	-12	-13	-26	-21	-27	-75
Net Cash Flow	-35	10	-6	17	-11	-3	-6	9	5	-4	-7	-4
Free Cash Flow	-13	54	36	5	-10	-4	59	41	-50	44	30	64
CFO/OP	64%	82%	75%	66%	102%	95%	98%	132%	90%	104%	139%	121%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	246	280	251	346	293	334	273	234	243	241	234	229
Inventory Days	58	59	61	100	89	93	121	96	86	109	86	118
Days Payable	130	94	139	88	50	86	96	89	88	66	64	103
Cash Conversion Cycle	173	245	173	357	332	342	298	241	241	283	257	244
Working Capital Days	183	207	335	452	336	401	322	258	300	294	258	274
ROCE %	24%	23%	19%	15%	19%	18%	12%	14%	13%	11%	9%	13%

Insights

In beta

Mar 2015

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Global Market Presence (Countries)
Number

xx	xx	xx	xx	xx	xx	xx	xx	xx	xx	xx
xx		xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx
	xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx	xxx
		xxx		xxx	xxx	xxx		xxx	xxx	xxx
		x,xxx		xxx	xxx	x,xxx		x,xxx	xxx	xxx
				x	x		x	x	x	x
								xx	xx	xx
									xx	xx
				x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx

Please log in to see hidden values.

Number of Branded Formulations/SKUs
Number

Total Employees
Number

Suppositories & Pessaries Capacity (Unit 2 & 3)
Million Units

Tablets Capacity (Palghar Unit 1)
Million Units

Total Manufacturing Units
Number

Dealer/Distributor Count
Number

Revenue Concentration - African Region
%

R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

12 Recently

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	35.12%	35.06%	34.97%	34.97%	34.90%	34.82%	35.10%	35.29%	35.44%	35.39%	35.36%	35.36%
	16.50%	16.31%	15.35%	14.74%	13.24%	12.13%	13.51%	13.18%	12.65%	13.27%	14.54%	10.45%
	6.62%	6.61%	6.60%	6.59%	6.58%	6.56%	6.55%	6.55%	6.54%	5.98%	5.78%	5.04%
	41.73%	42.00%	43.08%	43.71%	45.27%	46.49%	44.84%	44.98%	45.37%	45.36%	44.32%	49.15%
No. of Shareholders	42,182	43,234	40,758	45,157	44,737	52,937	49,558	49,517	46,707	44,461	43,380	44,874

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	60.16%	60.16%	41.60%	41.60%	33.31%	33.14%	35.04%	34.97%	35.29%	35.36%
	5.44%	10.84%	23.87%	24.16%	22.83%	17.33%	16.60%	14.74%	13.18%	10.45%
	0.25%	0.14%	1.62%	2.96%	6.72%	6.66%	6.63%	6.59%	6.55%	5.04%
	34.15%	28.86%	32.91%	31.28%	37.14%	42.87%	41.73%	43.71%	44.98%	49.15%
No. of Shareholders	15,811	19,930	15,010	14,151	28,543	45,866	43,041	45,157	49,517	44,874

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

Credit ratings

Concalls

Aug 2019

Transcript

AI Summary
PPT
May 2019

Transcript

AI Summary
PPT
Feb 2019

Transcript

AI Summary
PPT
Nov 2018

Transcript

AI Summary
PPT
Aug 2018

Transcript

AI Summary
PPT
May 2018

Transcript

AI Summary
PPT
Jan 2018

Transcript

AI Summary
PPT